Glioblastoma (GBM) is an aggressive adult brain tumor, and in spite of standard of care (SOC) with radiation therapy and chemotherapy with temozolomide tumor re-growth (or recurrence) and patient relapse are inevitable. There is compelling evidence that suggests SOC can debulk the tumor but cells endowed with treatment-resistant properties (e.g. expressing the protein marker CD133) […]
Read More